Results from a Pooled Analysis of Two European, Randomized, Placebo-Controlled, Phase 3 Studies of ATX-101 for the Pharmacologic Reduction of Excess Submental Fat
Tóm tắt
The injectable adipocytolytic drug ATX-101 is the first nonsurgical treatment for the reduction of submental fat (SMF) to undergo comprehensive clinical evaluation. This study aimed to confirm the efficacy and safety of ATX-101 for SMF reduction through a post hoc pooled analysis of two large phase 3 studies. Patients with unwanted SMF were randomized to receive 1 or 2 mg/cm2 of ATX-101 or a placebo injected into their SMF during a maximum of four treatment sessions spaced approximately 28 days apart, with a 12-week follow-up period. The proportions of patients with reductions in SMF of one point or more on the Clinician-Reported SMF Rating Scale (CR-SMFRS) and the proportions of patients satisfied with the appearance of their face and chin [Subject Self-Rating Scale (SSRS) score ≥4] were reported overall and in subgroups. Other efficacy measures included improvements in the Patient-Reported SMF Rating Scale (PR-SMFRS), calliper measurements of SMF thickness, and assessment of skin laxity [Skin Laxity Rating Scale (SLRS)]. Adverse events and laboratory test results were recorded. Significantly greater proportions of the patients had improvements in clinician-reported measures (≥1-point improvement in CR-SMFRS: 58.8 and 63.8 % of the patients who received ATX-101 1 and 2 mg/cm2, respectively, and 28.6 % of the placebo recipients; p < 0.001 for both ATX-101 doses vs. placebo) and patient-reported measures (≥1-point improvement in PR-SMFRS: 60.0 and 63.1 % of the patients who received ATX-101 1 and 2 mg/cm2, respectively, vs. 34.3 % of the placebo recipients; p < 0.001 for both), analyzed alone or in combination, with ATX-101 versus placebo. These improvements correlated moderately with patient satisfaction regarding face and chin appearance (SSRS score ≥4: 60.8 and 65.4 % of the patients who received ATX-101 1 and 2 mg/cm2, respectively, vs. 29.0 % of the placebo recipients; p < 0.001 for both). In this study, ATX-101 was effective irrespective of gender, age, or body mass index. Reduction in SMF with ATX-101 was confirmed by calliper measurements (p < 0.001 for both doses vs. placebo) and generally did not lead to worsening of skin laxity (SLRS improved or was unchanged: 91.3 and 90.5 % of the patients who received ATX-101 1 and 2 mg/cm2, respectively, and 91.6 % of the placebo recipients). Adverse events were mostly transient, mild to moderate in intensity, and localized to the treatment area. The findings show ATX-101 to be an effective and well-tolerated pharmacologic treatment for SMF reduction. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors
www.springer.com/00266
.
Tài liệu tham khảo
Co AC, Abad-Casintahan MF, Espinoza-Thaebtharm A (2007) Submental fat reduction by mesotherapy using phosphatidylcholine alone vs phosphatidylcholine and organic silicium: a pilot study. J Cosmet Dermatol 6:250–257
Patel BCK (2006) Aesthetic surgery of the aging neck: options and techniques. Orbit 25:327–356
Hatef DA, Koshy JC, Sandoval SE, Echo AP, Izaddoost SA, Hollier LH (2009) The submental fat compartment of the neck. Semin Plast Surg 23:288–291
Koehler J (2009) Complications of neck liposuction and submentoplasty. Oral Maxillofac Surg Clin N Am 21:43–52, vi
Wollina U, Goldman A, Berger U, Abdel-Naser MB (2008) Esthetic and cosmetic dermatology. Dermatol Ther 21:118–130
Stevens WG, Pietrzak LK, Spring MA (2013) Broad overview of a clinical and commercial experience with CoolSculpting. Aesthet Surg J 33:835–846
Fatemi A (2009) High-intensity focused ultrasound effectively reduces adipose tissue. Semin Cutan Med Surg 28:257–262
Rotunda AM, Kolodney MS (2006) Mesotherapy and phosphatidylcholine injections: historical clarification and review. Dermatol Surg 32:465–480
Hexsel D, Serra M, Mazzuco R, Dal’Forno T, Zechmeister D (2003) Phosphatidylcholine in the treatment of localized fat. J Drugs Dermatol 2:511–518
Rittes PG (2001) The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. Dermatol Surg 27:391–392
Rittes PG (2003) The use of phosphatidylcholine for correction of localized fat deposits. Aesthet Plast Surg 27:315–318
Klein SM, Schreml S, Nerlich M, Prantl L (2009) In vitro studies investigating the effect of subcutaneous phosphatidylcholine injections in the 3T3-L1 adipocyte model: lipolysis or lipid dissolution? Plast Reconstr Surg 124:419–427
Rotunda AM, Weiss SR, Rivkin LS (2009) Randomized double-blind clinical trial of subcutaneously injected deoxycholate versus a phosphatidylcholine–deoxycholate combination for the reduction of submental fat. Dermatol Surg 35:792–803
Park EJ, Kim HS, Kim M, Oh HJ (2013) Histological changes after treatment for localized fat deposits with phosphatidylcholine and sodium deoxycholate. J Cosmet Dermatol 12:240–243
Reeds DN, Mohammed BS, Klein S, Boswell CB, Young VL (2013) Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet Surg J 33:400–408
Noh Y, Heo CY (2012) The effect of phosphatidylcholine and deoxycholate compound injections to the localized adipose tissue: an experimental study with a murine model. Arch Plast Surg 39:452–456
Rotunda AM, Suzuki H, Moy RL, Kolodney MS (2004) Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg 30:1001–1008
Gupta A, Lobocki C, Singh S, Robertson M, Akadiri OA, Malhotra G, Jackson IT (2009) Actions and comparative efficacy of phosphatidylcholine formulation and isolated sodium deoxycholate for different cell types. Aesthet Plast Surg 33:346–352
Duncan D, Rubin JP, Golitz L, Badylak S, Kesel L, Freund J, Duncan D (2009) Refinement of technique in injection lipolysis based on scientific studies and clinical evaluation. Clin Plast Surg 36:195–209
Yagima Odo ME, Cuce LC, Odo LM, Natrielli A (2007) Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects. Dermatol Surg 33:178–188
Rotunda AM (2009) Injectable treatments for adipose tissue: terminology, mechanism, and tissue interaction. Lasers Surg Med 41:714–720
Thuangtong R, Bentow JJ, Knopp K, Mahmood NA, David NE, Kolodney MS (2010) Tissue-selective effects of injected deoxycholate. Dermatol Surg 36:899–908
Walker P, Lee D (2013) Open-label pharmacokinetic study to evaluate lipid levels in the blood following injections of ATX-101 (synthetically derived sodium deoxycholate). J Am Acad Dermatol 68:AB1 (Abstract P5917)
Rzany B, Griffiths T, Walker P, Lippert S, McDiarmid J, Havlickova B (2014) Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol 170:445–453
Ascher B, Hoffmann K, Walker P, Lippert S, Wollina U, Havlickova B (2014) Efficacy, patient-reported outcomes, and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.12377
Goodman G, Smith K, Lee D, Havlickova B, Walker P (2012) ATX-101, a pharmacological treatment for the reduction of submental fat: results of two pooled phase IIa studies. In: 21st Annual congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic, 27–30 September 2012 (Poster P259)
Dover J, Schlessinger J, Young L, Walker P (2012) Reduction of submental fat with ATX-101: results from a phase IIB study using investigator, subject, and magnetic resonance imaging assessments. J Am Acad Dermatol 66:AB29 (Abstract 4787)
Jones DH, Carruthers J, Walker P, Lee D, Lizzul PF, Beddingfield F (2014) REFINE-1, a multicenter, double-blind, randomized, placebo-controlled pivotal phase 3 study with ATX-101, an injectable drug for submental contouring. J Am Acad Dermatol 70:AB20
Humphrey S, Brandt FS, Walker P, Lee D, Lizzul PF, Beddingfield F (2014) REFINE-2: A multicenter, double-blind, randomized, placebo-controlled pivotal phase 3 study with ATX-101, an injectable drug for submental contouring. J Am Acad Dermatol 70:AB20
Walker P, Havlickova B, Lee D (2012) ATX-101 for reduction of submental fat: pharmacokinetic and safety findings from a phase I trial. In: 8th European Masters in Anti-Aging Medicine, Paris, France, 12–14 October 2012 (Poster)
Walker P, Lee D, Toth BA, Havlickova B (2013) Subcutaneously injected ATX-101 causes adipocytolysis and local inflammation: results of a phase I histology study. In: 1st Anti-Aging Medicine European congress, Paris, France, 11–12 October 2013 (Poster)
Smith K, Goodman G, Sapra S, Lee D, Walker P (2012) ATX-101 treatment offers long-term durability of submental fat reduction: preliminary follow-up study results of subjects from two phase 2A studies. In: 70th Annual meeting of the American Academy of Dermatology, San Diego, CA, USA, 16–20 March 2012 (Abstract 4899)
Mayo Clinic (2014) Neck-lift. http://www.mayoclinic.org/neck-lift/about.html. Accessed 28 March 2014
Abraham MT, Romo T, 3rd (2012) Liposuction of the face and neck: treatment and management. http://emedicine.medscape.com/article/842367-treatment#a1135. Accessed 28 March 2014
Paul M, Mulholland RS (2009) A new approach for adipose tissue treatment and body contouring using radiofrequency-assisted liposuction. Aesthet Plast Surg 33:687–694
Kamer FM, Minoli JJ (1993) Postoperative platysmal band deformity: a pitfall of submental liposuction. Arch Otolaryngol Head Neck Surg 119:193–196
Dover J, Schlessinger J, Young L, Havlickova B, Walker P (2012) Results from a phase IIb study evaluating the efficacy and safety of ATX-101 for reduction of submental fat using magnetic resonance imaging and investigator and subject assessment. In: 21st Annual congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic, 27–30 September 2012 (Poster P258)